CURE member Alexion Pharmaceuticals, which is scheduled to move to new headquarters in New Haven, has been in the news recently.

  • The company has initiated a single, multinational, placebo-controlled trial to evaluate the safety and efficacy of eculizumab (Soliris®) in patients with relapsing neuromyelitis optica, a life-threatening, ultra-rare neurologic disorder. Alexion also initiated a single, multinational, placebo-controlled trial in patients with refractory generalized myasthenia gravis, another rare and debilitating neurologic disorder … more

  • The European Commission has granted an orphan drug designation to Soliris® for the prevention of graft rejection following solid organ transplantation … more

  • Alexion announced the appointment of John T. Mollen, most recently special advisor to the Chairman of EMC Corporation, to Alexion’s board of directors … more

  • A recent article in the Yale Daily News points out that Alexion’s move to New Haven is one of several developments in the past few years that have catapulted the city into a position as a major biotech player nationwide … more


4/29 4:00 pm – 6:00 pm
Yale & CURE BioHaven presents ‘Melinta Therapeutics: The Road from the Lab to New Medicines’ more

5/12 5:00 pm – 6:30 pm in New Haven
BioScienceClubhouseCT presents ‘SystaMedic: A Novel Cause-Effect Analysis Platform for Predicting Probability of R&D Program Success’  more